|Pernix Therapeutics Inc. Reports First Quarter 2015 Financial Results|
MORRISTOWN, NJ – May 1, 2015 – Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2015.
“We are pleased to have recently closed the Zohydro ER acquisition, which represents an outstanding opportunity for growth, both organically and through life cycle management, and an important strategic fit for our focus on CNS disorders,” said Doug Drysdale, Chairman, President and Chief Executive Officer.
“While up 78% year over year, our first quarter revenues fell short of Q4 2014 levels largely due to softness in Treximet sales resulting from timing-related challenges, which were partially offset by Silenor growth. We are encouraged that Treximet has responded positively to the release of single dose samples in late March and we feel confident in our ability to positively direct the trajectory of the Treximet business.”
“Our sales force efforts continue to drive Silenor growth, as demonstrated by the 66% increase in total prescriptions and 79% increase in new prescriptions in the first quarter of 2015 over the prior year quarter. With samples now in hand, we look forward to replicating this success with Treximet as well as Zohydro ER with BeadTek, which we expect to launch next week.”
“The fundamentals of our business are strong. Each of our three strategically promoted brands address large market opportunities and have significant growth potential. Coupled with the ongoing advancement of multiple R&D projects intended to build value within our portfolio, and multiple opportunities for additional synergistic acquisitions, we are well positioned to deliver long-term shareholder value.”
For the first quarter of 2015, net revenues were $33.9 million, an increase of $14.8 million or 78% as compared to $19.1 million for the first quarter of 2014. A summary of net revenues is outlined below (in millions):
The year over year comparison benefits from a more focused selling and marketing strategy for Silenor that included a price increase that was implemented during the second half of 2014, and the addition of Treximet, which we began selling in September 2014. These increases were offset by the discontinuation of certain less profitable products, primarily generics, and certain OTC monograph seasonal cough and cold products; the termination of certain contracts pursuant to which we marketed and distributed products for others; and the increase of certain deductions such as managed care rebates on certain brand products.
We recorded no manufacturing revenue during the first quarter of 2015 compared with $871,000 during the same period in 2014, due to the sale of our manufacturing subsidiary in April 2014.
Gross profit margin as a percentage of net revenues was 67.3% during the three months ended March 31, 2015, compared to 47.7% for the three months ended March 31, 2014. The increase was primarily due to a change in product mix to include the Treximet product line. Cost of product sales will increase in correlation to growing sales of Treximet and Silenor, which will result in higher royalty expense as well as costs of goods sold.
Selling, general and administrative (SG&A) expenses in the first quarter of 2015 increased to $21.0 million, compared to $13.6 million for the first quarter of 2014, driven primarily by higher marketing costs related to Silenor and Treximet, and increases in personnel, legal settlement, and training costs. These increases were partially offset by savings of $1.7 million related to the sale of our manufacturing facility in April 2014. Bad debt expense, consulting and insurance costs also decreased in the 2015 quarter.
Research and Development expenses were essentially flat during the first quarter of 2015. Treximet related R&D expense increased by $481,000, while R&D expenses related to other projects decreased by $456,000.
Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, a non-GAAP measure) was $4.6 million for the first quarter of 2015 and a loss of $2.0 million for the first quarter of 2014. See the table at the end of this press release for a reconciliation of net income to Adjusted EBITDA.
Depreciation and amortization expense was $18.4 million for the first quarter of 2015, compared to $2.2 million for the first quarter of 2014. The increase was primarily a result of $16.4 million of amortization related to the acquisition of Treximet developed technologies, partially offset by a decrease in depreciation expense of $81,000, primarily due to the sale of PML and its related fixed assets in April 2014.
Interest expense for the three months ended March 31, 2015 was $9.4 million compared to $1.4 million for the first quarter of 2014. The increase was primarily driven by interest related to our $220.0 million Treximet Notes, issued in August 2014 and $65.0 million February 2014 Convertible Notes, issued in February 2014, of $6.6 million and $1.3 million, respectively.
The Company recognized an income tax benefit of $4.6 million for the first quarter of 2015, compared to an income tax benefit of $5.9 million in the first quarter of 2014.
The net loss for the first quarter of 2015 was $23.7 million, or $0.62 per basic and diluted share, compared to net loss of $9.5 million, or $0.26 per basic and diluted share, for the first quarter of 2014. Weighted average common shares outstanding were 38.5 million and 37.3 million per basic and diluted shares for the first quarter of 2015 and 2014, respectively. On a non-GAAP basis, 1Q 2015 adjusted net loss was $4.0 million versus an adjusted net loss of $1.8 million last year.
As of March 31, 2015, the Company had $18.9 million of cash and approximately $10.7 million available under its revolving line of credit, subject to borrowing base capacity. Total debt at the end of the quarter was $295.7 million, including $14.5 million of current debt and $281.1 million of long term debt.
On April 22, 2015, Pernix completed a private offering of $130 million of 4.25% Convertible Senior Notes due 2021 to qualified institutional buyers. The Company used $80.9 million of the proceeds to finance the cash consideration portion of Zohydro® ER franchise; approximately $8.3 million to pay fees and expenses related to the acquisition and the offering, and up to $2.2 million to pay the consent fee related to the previously announced consent solicitation of its 12.00% senior secured notes due 2020. The remaining $38.6 million will be used for working capital and other general corporate purposes.
On a pro- forma basis, Pernix had cash and cash equivalents of $57.5 million and $360.7 million of debt as of March 31, 2015. For the balance of the year, Pernix anticipates cash interest expense for its 12% Senior Secured Notes due 2020 and its 4.25% Senior Convertible Notes due 2021 will be approximately $16 million.
The webcast of the call will be archived for 30 days via the Investors section of the Company’s website (click here)
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments.
To learn more about Pernix Therapeutics, visit www.pernixtx.com
Treximet® and Silenor® are registered trademarks of Pernix Therapeutics Holdings, Inc.
Non-GAAP Financial Measures
Pernix is disclosing non-GAAP financial measures in this press release. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our operating results because they exclude amounts that management and the board of directors do not consider part of core operating results or that are non-recurring when assessing the performance of the organization. Primarily due to acquisitions, Pernix believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with U.S. generally accepted accounting principles (GAAP). In addition to disclosing its financial results determined in accordance with GAAP, Pernix is disclosing non-GAAP results that exclude items such as amortization expense and certain other expense and revenue items in order to supplement investors’ and other readers’ understanding and assessment of the Company’s financial performance. Whenever Pernix uses a non-GAAP measure, it will provide a reconciliation of non-GAAP financial measures to the most closely applicable GAAP financial measure. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures set forth herein and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “target” or similar expressions are forward-looking statements. Because these statements reflect the Company’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption “Risk Factors” in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect the Company’s future financial results and could cause actual results to differ materially from those expressed in forward-looking statements contained in the Company’s Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
PERNIX THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARIES
PERNIX THERAPEUTICS HOLDINGS, INC.
PERNIX THERAPEUTICS HOLDINGS, INC.
Supplemental Financial Information
The following table presents a reconciliation of Pernix’s net loss to adjusted EBITDA. The Company defines EBITDA as net income plus interest, income tax expense, depreciation and amortization and presents these measures to assist investors in evaluating Pernix’s operating performance and comparing the Company’s results with those of other companies. Adjusted EBITDA should not be considered in isolation from or as a substitute for net income.
PERNIX THERAPEUTICS HOLDINGS, INC.
PERNIX THERAPEUTICS HOLDINGS, INC.